SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ATNM

Actinium Pharmaceuticals, Inc. (ATNM)

NYSE: ATNM · USD
Healthcare · Biotechnology
$1.05-$0.02 (-1.87%)
 
Market cap
$33.0M
Insider Score
Analyst consensus
Market Cap$33.01M-18.6%
Revenue (ttm)$35.00M
Net Income$10.60M
EPS$0.43
Shares Out31.44M
PE Ratio2.44
Forward PE-2.28
Dividendn/a
Ex-Dividend Daten/a
Volume280,659
Open$1.07
Previous Close$1.07
Day's Range$1.00 - $1.10
52-Week Range$0.73 - $1.72
Betan/a
AnalystsStrong Buy
Price Target$4.50(+328.57%)
Earnings Daten/a

About ATNM

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Address
100 Park Avenue, New York, NY, 10017, United States
Market Cap
33 million
Employees
25
Industrial Classification
Biotechnology
1 Day
-1.87%
5 Days
-35.98%
1 Month
-34.38%
6 Months
-11.02%
1 Year
-18.60%

$ATNM stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ATNM holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ATNM's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ATNM Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ATNM Revenue by Segment

$140.10MTotal
Recognized upfront payment$35.00M24.98%
Other revenue$35.00M24.98%
Claim amount$35.00M24.98%
Non-refundable payment received$35.00M24.98%
Grant revenue$100.00K0.07%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ATNM patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ATNM from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from ATNM’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
72

News check: Multiple positive clinical trial milestones, SAB formation, and progress on lead asset ATNM-400 demonstrate pipeline advancement without negative catalysts.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.05%

Weight is the stock’s share of each fund’s holdings.